Amylyx Pharmaceuticals to Remove ALS Drug from Market

Amylyx Pharmaceuticals has announced that it will voluntarily remove its drug for amyotrophic lateral sclerosis (ALS) from the market. This decision comes after a recent clinical trial showed that the treatment is ineffective. The company has already started the process of removing the drug, called Relyvrio in the United States and Albrioza in Canada, from the market. New patients will no longer have access to the drug, but existing patients can be transitioned to a free drug program.

In addition, Amylyx will reduce its staff by 70 percent. The company stated that this decision was made in partnership with stakeholders and is in line with their commitment to patients with ALS and other neurodegenerative diseases

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Amylyx Pharmaceuticals to Pull Drug for Lou Gehrig’s Disease from MarketAmylyx said last month it was considering pulling its drug Relyvrio after a clinical trial in 600 patients failed to show any improvements in survival or other health measures. The maker of the drug has now announced that it will voluntarily halt sales and marketing of the drug, acknowledging its lack of effectiveness in helping patients with the deadly neurological condition.
مصدر: nbcsandiego - 🏆 524. / 51 اقرأ أكثر »

Why Amylyx is pulling ALS drug Relyvrio from US market after studyThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.
مصدر: AP - 🏆 728. / 51 اقرأ أكثر »